Welcome to our dedicated page for Ge Healthcare Technologies SEC filings (Ticker: GEHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GE HealthCare Technologies Inc. filings document formal disclosures for a medical technology and diagnostics company, including Form 8-K reports on results of operations and financial condition, material agreements, capital-structure matters, and governance changes. Recent current reports include earnings releases, a senior unsecured revolving credit facility, and board-related disclosures.
The company’s proxy materials describe annual-meeting matters, director elections, board committee assignments, executive compensation, equity awards, and shareholder voting procedures. GEHC filings also provide formal context for segment performance, liquidity arrangements, credit covenants, and governance matters tied to its healthcare technology, software, and pharmaceutical diagnostics businesses.
GE HealthCare Technologies Chief Accounting Officer George A. Newcomb reported equity compensation activity tied to performance stock units. On February 12, 2026, he acquired 2,523 shares of common stock at $0 per share when PSUs granted on March 1, 2023 vested after performance criteria were certified.
On the same date, 802 shares at $79.2 per share were withheld to cover tax obligations arising from the PSU vesting, a non-market disposition. After these transactions, he directly owned 9,318 shares of common stock and indirectly held 12 additional shares through a family member.
GE HealthCare Technologies Inc. CEO Kevin Michael O'Neill reported equity award activity in company stock. On February 12, 2026, he acquired 6,938 shares of common stock at $0 per share through the vesting of previously granted performance stock units after performance criteria were certified.
To cover related tax withholding obligations from this vesting, 3,261 shares were disposed of at a price of $79.2 per share. Following these transactions, O'Neill directly held 26,195 shares of GE HealthCare common stock and indirectly held 59 shares through a share incentive plan trust.
GE HealthCare Technologies Inc. CEO Philip Rackliffe reported equity transactions tied to performance stock units (PSUs). On February 12, 2026, 3,154 shares of common stock were acquired at $0 per share upon PSU vesting after performance criteria were certified.
To cover related tax obligations, 1,174 shares were disposed of through a tax-withholding transaction at $79.2 per share. Following these transactions, Rackliffe directly owned 17,373 shares of GE HealthCare common stock.
GE HealthCare Technologies executive Roland Rott, CEO of Imaging, reported equity award activity in company stock. On February 12, 2026, he acquired 7,885 shares of common stock at $0 per share from the vesting of previously granted performance stock units after performance goals were certified. On the same date, 3,943 shares were disposed of at $79.2 per share to cover tax withholding tied to that vesting, a non-open-market transaction. After these entries, he directly owned 32,506 shares of GE HealthCare common stock.
GE HealthCare Technologies Inc.’s Chief Technology Officer, Kass-Hout Taha, reported equity transactions in company common stock. On February 12, 2026, he acquired 23,339 shares at $0 per share through the vesting of performance stock units granted on March 1, 2023, after performance criteria were certified as met. On the same date, 7,787 shares were disposed of at $79.20 per share to cover tax withholding obligations related to this vesting. Following these transactions, he directly owned 79,655 shares of GE HealthCare common stock.
GE HealthCare Technologies’ GC & Corporate Secretary Frank R. Jimenez reported equity compensation activity involving company common stock. On February 12, 2026, he acquired 22,078 shares at $0 per share through the vesting of performance stock units granted on March 1, 2023, after performance goals were certified as met. On the same date, 8,357 shares were disposed of at $79.20 per share to cover tax withholding obligations tied to this vesting, a non‑market, tax-related transaction. Following these entries, he directly owned 81,267 shares of GE HealthCare common stock.
SACCARO JAMES reported multiple insider transaction types in a Form 4 filing for GEHC. The filing lists transactions totaling 31,180 shares at a weighted average price of $79.20 per share. Following the reported transactions, holdings were 80,256 shares.
GE HealthCare Technologies President and CEO Peter J. Arduini reported equity award activity involving company common stock. On February 12, 2026, he acquired 74,908 shares at $0 upon vesting of previously granted performance stock units, after performance goals were certified as met. On the same date, 33,445 shares were disposed of at $79.20 per share to satisfy tax withholding obligations related to this vesting. Following these transactions, Arduini directly beneficially owned 206,135 shares of GE HealthCare common stock.
Dodge & Cox has disclosed a significant holding in GE HealthCare Technologies Inc. The firm reports beneficial ownership of 31,211,229 shares of GE HealthCare common stock, representing 6.9% of the class as of 12/31/2025.
Dodge & Cox has sole power to vote 29,588,129 shares and sole power to dispose of 31,211,229 shares, with no shared voting or dispositive power. The shares are held for clients of Dodge & Cox, who have the right to receive dividends and sale proceeds. Dodge & Cox certifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control of GE HealthCare.
GE HealthCare Technologies Inc. files its annual report describing its 2025 performance, business structure, and key risks. The company is a global healthcare solutions provider focused on advanced medical technology, pharmaceutical diagnostics, and AI-, cloud- and software-based tools for clinicians.
GE HealthCare operates four segments: Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics, serving hospitals and health systems in over 160 countries. The business combines large installed equipment, recurring consumables, service contracts, and digital solutions, and notes that fourth-quarter results are typically stronger due to customer spending patterns.
The company, spun off from General Electric in January 2023, reports approximately 54,000 employees, including 11,100 engineers and scientists and extensive global sales and service networks. As of June 30, 2025, non‑affiliate shareholders held common stock with an aggregate market value of about $34 billion, and 455,749,767 shares were outstanding as of January 28, 2026. The report highlights extensive regulatory, cybersecurity, competition, reimbursement, geopolitical, and data‑privacy risks that could affect future results.